Analysis of the uses, efficacy and clinical manifestations of Shafinamide Tablets (Siddaco) in patients with Parkinson's disease

Safinamide tablets (Safinamide) is an oral reversible monoamine oxidase-B (MAO-B) inhibitor that simultaneously blocks sodium channels and modulates glutamate release. This unique dual mechanism of action allows it to not only increase the central concentration of dopamine, but also regulate excitatory neurotransmission, thereby exerting multi-faceted effects in the treatment of Parkinson's disease (PD). Safinamine is mainly used for patients with moderate to advanced Parkinson's disease, especially as a synergistic drug for combined treatment with levodopa (Levodopa) to improve movement fluctuations and "on-off" phenomena.

Clinical studies show that safinamide can significantly prolong the "on state" time, reduce the patient's daily "off state" time, and improve motor function. Compared with levodopa alone, patients treated with safinamine showed more stable motor control in areas such as daily activities, walking, standing, and hand movements. Long-term follow-up data suggest that safinamine can improve patients' quality of life by reducing the incidence of motor complications, such as tardive dyskinesia or dyskinesia, while maintaining the efficacy of levodopa.

In terms of non-motor symptoms, some studies have shown that safinamine also has a certain auxiliary effect on depression, fatigue and cognitive function. This may be related to its inhibition of MAO-B increasing dopamine and regulating glutamate activity, but this effect requires further large-scale clinical verification. While patients are taking safinamine, common adverse reactions include mild headache, insomnia, blood pressure fluctuations or gastrointestinal discomfort, but the overall tolerance is good. Compared with other Parkinson's drugs, safinamide has a lower incidence of side effects and does not significantly increase the risk of hallucinations or psychotic symptoms.

Overall, the clinical application of safinamide tablets in patients with Parkinson's disease has shown significant improvement in motor symptoms, improvement in quality of life, and potential to assist non-motor symptoms. Its dual mechanism of action gives it unique advantages in combination treatment regimens, especially for patients with mid-to-late stage motor fluctuations. In clinical use, doctors usually develop individualized medication plans based on the patient's motion fluctuation characteristics, age, concomitant medications, and potential risks of adverse reactions to maximize efficacy and safety.

Keyword tags:

Safinamide tablets, Parkinson's disease,MAO-BInhibitors, uses, efficacy, clinical manifestations, side effects, motor fluctuations

Reference materials:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875947/